B CELL MALIGNANCIES
Clinical trials for B CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new B CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for B CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Boosting antibody takes on tough blood cancers
Disease control Recruiting nowThis study tests an experimental drug called AZD5492 in about 174 adults with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to at least two prior treatments. The drug is designed to help the body's own T cells find and attack cancer ce…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Engineered immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called 4SCAR19 cells for people with B-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The trial aims to check safety…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New combo immune therapy takes on hard-to-treat blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. It uses a mix of specially designed immune cells (CAR-T cells) that target up to seven different markers on cancer cells. The goal is to see if this com…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New CAR T-Cell therapy targets tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called SHB-04-CD22, which uses a patient's own immune cells (T-cells) engineered to find and attack cancer cells that have a protein called CD22. It is for children and adults (ages 1-80) with B-cell cancers that have come back or not responded to…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug duo aims to deepen leukemia remission
Disease control Recruiting nowThis study tests whether adding emavusertib to a standard targeted therapy (zanubrutinib) can improve outcomes for people with chronic lymphocytic leukemia (CLL) and other B-cell cancers. About 108 adults with CLL who have already received some treatment will take both drugs. The…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
MRNA technology takes on blood cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new mRNA drug that targets a protein called CD19 on cancer cells. It is for people with B-cell blood cancers (like lymphoma or leukemia) who have no standard treatment options left. The goal is to find a safe dose and see if the drug can shrink tumo…
Matched conditions: B CELL MALIGNANCIES
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC